Archivos de bronconeumología
-
In both thromboembolic disease and pulmonary hypertension, 2010 has been a prodigious year for interesting publications. Some data have helped to elucidate the factors associated with a greater risk of thromboembolic disease, such as long journeys and certain polymorphisms. New recommendations on diagnosis have been made, giving a greater role to computed tomography angiography. ⋯ Some drugs are highlighted in the literature. Imatinib is promising but probably only in some patients. Riociguat provides good results and inhaled treprostinil has emerged as a new option.
-
The Respiratory Nursing and Physiotherapy Section of the Spanish Society of Pneumology and Thoracic Surgery, established as a working group more than 19 years ago, has been characterized by a high degree of involvement and collaboration with all the research studies requiring nursing and physiotherapy techniques. However, publication of articles by this collective is scarce compared with that of the rest of the Society and the characteristics, attitudes and limitations of this section pose an obstacle to increasing the number of its publications. This article aims to explain some of the possible reasons that could have given rise to this situation. The new tendencies and the attitude of this collective and the rest of the Society are encouraging and suggest that the work of the Respiratory Nursing and Physiotherapy Section will be better reflected in the future.
-
Arch. Bronconeumol. · Jan 2011
[Advances in respiratory health 2010: the perspective from the Smoking and Health Section].
The Smoking and Health Section of the Spanish Society of Pneumology and Thoracic Surgery has been highly active in research throughout 2010. Many of the research studies performed have led to interesting publications. The present article analyzes the main clinical and basic research articles published by the distinct members of the Society's Smoking and Health Section. The various disciplines included under the heading of smoking are reviewed: diagnosis and treatment, epidemiology, genetics, bibliometry and tobacco-related diseases.
-
Current clinical guidelines recommend a step-wise approach to the pharmacological treatment of chronic obstructive pulmonary disease (COPD), with drugs being added according to the severity of airflow obstruction, symptoms, and the number of acute exacerbations in patients with severe disease. However, greater knowledge of the physiopathogenesis of this disease has led to COPD being considered a heterogeneous process in which therapeutic decisions should not be based exclusively on the results of spirometry. Treatment is increasingly individualized according to the patient's characteristics. The present article reviews the scientific evidence on the aims of treatment in COPD and the benefits achieved by the various pharmacological options available.
-
Patients with chronic obstructive pulmonary disease (COPD) and associated bronchitis are at higher risk of exacerbations, which are a major cause of morbidity and impaired quality of life. Moreover, exacerbations are associated with more rapid disease progression and higher mortality. ⋯ The results of clinical trials indicate that, in patients with COPD associated with chronic bronchitis and a history of exacerbations, roflumilast improves pulmonary function and reduces the symptoms and frequency of exacerbations requiring medical intervention. This effect is maintained when regular treatment with a long-acting bronchodilator or an inhaled corticosteroid is added.